Key Takeaways
- • Bain Capital Private Equity and Cinven have entered definitive agreements to acquire Lonza Specialty Ingredients (LSI) for CHF 4.2 billion enterprise value, representing a significant midmarket private equity transaction in the specialty chemicals sector.
- • LSI operates as a global leader in microbial control solutions with approximately 2,800 employees, 11 R&D centers, and 17 manufacturing sites worldwide, serving approximately 5,300 customers across professional hygiene, home & personal care, disinfectants, preservatives, and industrial coatings end-markets.
- • The acquisition targets a business benefiting from structural market growth driven by favorable regulatory dynamics, increasing penetration of microbial control products, and heightened societal focus on hygiene and protection from harmful microorganisms.
- • LSI maintains leading market positions in North America and Europe with established customer relationships, proprietary intellectual property, regulatory expertise, and a unique production facility in Switzerland that will remain a focal point for collaboration between the consortium and Lonza AG.
- • The transaction is expected to close in the second half of 2021, subject to customary closing conditions, with the consortium planning to reinforce LSI's market position through accelerated R&D investment and innovation initiatives.
Summary
Bain Capital Private Equity and Cinven have signed definitive acquisition agreements for Lonza Specialty Ingredients, a division of Lonza AG headquartered in Basel, Switzerland, valuing the business at CHF 4.2 billion enterprise value. The transaction represents a strategic acquisition of a global specialty chemicals manufacturer focused on microbial control solutions—products essential for disinfectants, preservatives, sanitizers, personal care formulations, and industrial coatings applications.
LSI operates a substantial global footprint with approximately 2,800 employees distributed across 11 research and development centers and 17 manufacturing facilities worldwide. The business maintains a diversified customer base of approximately 5,300 accounts across multiple end-markets, with particular strength in the professional hygiene and home & personal care segments. The company holds leading competitive positions in North America and European markets, supported by longstanding customer relationships and deep regulatory expertise developed over its operational history.
The investment thesis reflects structural tailwinds in the microbial control solutions market, driven by favorable regulatory trends, expanding market penetration, and sustained demand for hygiene and antimicrobial protection products. LSI's competitive moat rests on differentiated product offerings underpinned by robust R&D capabilities, intellectual property protections, and regulatory certifications that create barriers to entry. The consortium intends to enhance LSI's market position through continued investment in research and innovation while collaborating closely with Lonza AG, particularly regarding the strategically important Visp manufacturing site.
The transaction is anticipated to close during the second half of 2021, subject to customary regulatory approvals and closing conditions. Kirkland & Ellis is providing legal counsel to the acquiring consortium. Upon completion, this acquisition will allow Lonza AG to reallocate capital and strategic focus, while establishing a dedicated specialty chemicals platform under experienced private equity operators.
LSI operates a substantial global footprint with approximately 2,800 employees distributed across 11 research and development centers and 17 manufacturing facilities worldwide. The business maintains a diversified customer base of approximately 5,300 accounts across multiple end-markets, with particular strength in the professional hygiene and home & personal care segments. The company holds leading competitive positions in North America and European markets, supported by longstanding customer relationships and deep regulatory expertise developed over its operational history.
The investment thesis reflects structural tailwinds in the microbial control solutions market, driven by favorable regulatory trends, expanding market penetration, and sustained demand for hygiene and antimicrobial protection products. LSI's competitive moat rests on differentiated product offerings underpinned by robust R&D capabilities, intellectual property protections, and regulatory certifications that create barriers to entry. The consortium intends to enhance LSI's market position through continued investment in research and innovation while collaborating closely with Lonza AG, particularly regarding the strategically important Visp manufacturing site.
The transaction is anticipated to close during the second half of 2021, subject to customary regulatory approvals and closing conditions. Kirkland & Ellis is providing legal counsel to the acquiring consortium. Upon completion, this acquisition will allow Lonza AG to reallocate capital and strategic focus, while establishing a dedicated specialty chemicals platform under experienced private equity operators.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.